Controversial New Alzheimer’s Drug Approved Despite Reservations
Follow via Flickr Link: https://www.flickr.com/photos/alzmglc/15311519476/in/photolist-pk2xi7-p5zz1T-pn36eW-pk2z4G-pn4Zzt-p5yHLJ-p5yCyQ-p5yy7H-p5yKrY-p5zBtP-pn2YxE-pn4BVM-p5ztkA-pmMonT-p5ziQo-bxQfpz-pmMxTM-p5zXeR-p5zbib-p5zQFk-pn3m45-pk2Tsf-p5zB8E-pn4N6g-4eGjGS-CFX1-pk2JQf-WfWjgu-pk2Lc3-3hQn2G-4kkzZx-6DojR2-51m44-7rJbFK-9YAmBr-fkWSC9-44Aksc-nSqng6-GAH7BD-j1M1Sk-gv1YhP-6Doi7x-3xK9k-6DoitF-dwaKm8-fkWSGw-6DoiYK-6DssxN-MhcFWN-o17RFw
The U.S. Food and Drug Administration has approved the first new drug for Alzheimer’s disease in 20 years, but some doctors, including one at UAB, warned patients’ families not to expect much from the drug any time soon.
The drug, aducanumab, is expected to help slow the progression of the disease, but not to improve current memory impairments, according to a release from the University of Alabama at Birmingham. The university’s Division of Memory Disorders and the Alzheimer’s Disease Center have been involved in clinical trials of aducanumab for the past five years.
“The approval of the first disease-modifying therapy is a milestone for our field and a result of years of intense research. However, it must be understood that [aducanumab] is not expected to restore memory or reverse the symptoms of Alzheimer’s disease,” said Dr. David Geldmacher, professor of neurology at UAB and clinical core director of the center. “Instead, it is expected to slow the worsening of the disease. [Aducanumab] is likely the beginning of a new era in treating AD, but not the end of the story.”
Geldmacher said it would be some time before the drug is widely available, not all patients will be eligible to receive it, and many patients, especially with advanced disease, are not likely to see improvement from it.
The FDA approved the drug despite opposition from an independent advisory committee and some Alzheimer’s experts who said there was not enough evidence the drug helps patients, according to several news reports, including from the Associated Press.
The FDA did require the drugmaker, Biogen, to conduct another study to determine whether it benefits patients, and it could pull the drug from the market if its effectiveness is not proven.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Are you a military veteran who has been charged money to apply for VA benefits?
If you're a veteran who has been charged a fee to get help on your application for a VA disability rating or other benefits, NPR wants to hear from you!
As Anna Wintour shifts her focus, ‘Vogue’ is looking for a new U.S. editor
Vogue magazine in the U.S. will soon have a new editorial head. Anna Wintour announced that, after nearly 40 years in the position, she will be focus on her wider roles at Vogue and Condé Nast.
Asked to flag ‘negative’ National Park content, visitors gave their own 2 cents instead
Signs installed earlier in National Parks earlier in June asked for feedback on signs "that are negative about past or living Americans." Comments viewed by NPR didn't provide the requested feedback.
Trump still would have won in 2024 even if everyone had turned out to vote, Pew finds
In 2024, 64% of the eligible-voting population turned out, the second highest in 120 years. New data show that even if all those voters who stayed home had voted, Trump would still be president today.
RFK Jr.’s vaccine advisers raise disproven fears about the preservative thimerosal
The CDC's Advisory Committee on Immunization Practices voted on the flu vaccine, raising concerns about a rarely used preservative. Medical groups worry this will "sow distrust" in vaccines.
How does President Trump make his money? Real estate, hospitality and his name
President Trump's financial disclosure shows more than $630 million in income from 2024 including tens of millions from cryptocurrency and Trump-branded products touted on the campaign trail.
